Rad17 Inhibitors
The Rad17 inhibitors constitute a diverse array of chemicals designed to modulate the activity of Rad17, a critical protein involved in DNA damage response and cell cycle regulation. One notable example is Caffeic Acid Phenethyl Ester (CAPE), which indirectly inhibits Rad17 by suppressing the AKT pathway. This suppression results in reduced Rad17 activity, impairing its role in facilitating proper cell cycle progression and DNA damage repair. Several other inhibitors, such as AZD7762 and VE-821, target upstream components of the DNA damage response cascade. AZD7762, a CHK1 inhibitor, disrupts Rad17 function by preventing its phosphorylation via the CHK1 pathway. Similarly, VE-821, an ATR inhibitor, interferes with the ATR pathway, leading to impaired Rad17-mediated responses to DNA damage. These indirect inhibitory effects highlight the interconnectedness of the signaling pathways involved in Rad17 regulation.
In addition, compounds like SB203580 and Roscovitine influence downstream elements of Rad17's signaling network. SB203580, a p38 MAPK inhibitor, disrupts the p38 MAPK pathway downstream of Rad17, affecting its cell cycle regulatory functions. Roscovitine, a CDK inhibitor, modulates the CDK pathway, further underscoring the intricate network of interactions that govern Rad17 activity. The Rad17 inhibitors collectively offer a sophisticated approach to modulating Rad17 function, either directly through active site binding or indirectly by influencing pathways related to its regulation. This diverse repertoire of chemicals provides researchers with powerful tools for unraveling the complexities of Rad17-mediated processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Caffeic acid phenethyl ester | 104594-70-9 | sc-200800 sc-200800A sc-200800B | 20 mg 100 mg 1 g | $70.00 $290.00 $600.00 | 19 | |
CAPE inhibits Rad17 indirectly by suppressing the AKT pathway, which is involved in Rad17 activation. Inhibition of AKT leads to reduced Rad17 activity and impaired cell cycle progression. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762 is a CHK1 inhibitor that indirectly inhibits Rad17 by preventing its phosphorylation via the CHK1 pathway. This disruption hinders Rad17 function in DNA damage response and cell cycle control. | ||||||
SB 218078 | 135897-06-2 | sc-203692 | 1 mg | $133.00 | 1 | |
SB218078, a CDK2 inhibitor, indirectly inhibits Rad17 by influencing the CDK2 pathway, a downstream target of Rad17. Inhibition of CDK2 disrupts Rad17-mediated cell cycle regulation. | ||||||
NU6027 | 220036-08-8 | sc-215591 | 10 mg | $153.00 | 1 | |
NU6027, a DNA-PK inhibitor, indirectly inhibits Rad17 by affecting the DNA-PK pathway, which interacts with Rad17 in response to DNA damage. Inhibition of DNA-PK disrupts Rad17 function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD0332991, a CDK4/6 inhibitor, indirectly inhibits Rad17 by disrupting the CDK4/6 pathway, which is downstream of Rad17 in cell cycle regulation. Inhibition of CDK4/6 affects Rad17-mediated processes. | ||||||
LY2606368 | 1234015-52-1 | sc-507521 sc-507521A sc-507521B sc-507521C sc-507521D sc-507521E | 5 mg 10 mg 25 mg 100 mg 1 g 10 g | $176.00 $300.00 $500.00 $1900.00 $8000.00 $25000.00 | ||
LY2606368, a CHK1/2 inhibitor, indirectly inhibits Rad17 by disrupting CHK1/2-mediated phosphorylation of Rad17. This disruption impairs Rad17 function in DNA damage response and cell cycle control. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
VE-821, an ATR inhibitor, indirectly inhibits Rad17 by disrupting the ATR pathway, which interacts with Rad17 in response to DNA damage. Inhibition of ATR disrupts Rad17 function in cell cycle regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine, a CDK inhibitor, indirectly inhibits Rad17 by influencing the CDK pathway, a downstream target of Rad17. Inhibition of CDK disrupts Rad17-mediated cell cycle regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly inhibits Rad17 by suppressing the PI3K/Akt pathway, which negatively regulates Rad17 activity. Inhibition of PI3K leads to reduced Rad17 function in DNA damage response. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
VX-11e, a dual ATR/CHK1 inhibitor, indirectly inhibits Rad17 by disrupting both the ATR and CHK1 pathways. Inhibition of these pathways impairs Rad17 function in DNA damage response and cell cycle control. | ||||||